Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H31N3O3 |
Molecular Weight | 385.4998 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC=C1N2CCN(CCN3C(=O)CC4(CCCC4)CC3=O)CC2
InChI
InChIKey=AYYCFGDXLUPJAQ-UHFFFAOYSA-N
InChI=1S/C22H31N3O3/c1-28-19-7-3-2-6-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16176444 | https://www.ncbi.nlm.nih.gov/pubmed/7713154Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1970304
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176444 | https://www.ncbi.nlm.nih.gov/pubmed/7713154
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1970304
BMY-7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3. BMY-7378 was at the preclinical stage of development for the treatment of anxiety disorders, but later was discontinued.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176444 | https://www.ncbi.nlm.nih.gov/pubmed/1970304
Curator's Comment: CNS active in animal models
Originator
Sources: http://adisinsight.springer.com/drugs/800001317
Curator's Comment: # Bristol-Myers Squibb
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176444 |
6.54 null [pKi] | ||
Target ID: CHEMBL223 |
8.2 null [pKi] | ||
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7713154 |
8.3 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635. | 1997 |
|
Characterization of alpha1-adrenoceptor-mediated contraction in the mouse thoracic aorta. | 2001 Jul 20 |
|
The hypotensive effect of BMY 7378 is antagonized by a silent 5-HT(1A) receptor antagonist: comparison with 8-hydroxy-dipropylamino tetralin. | 2001 Sep-Oct |
|
alpha(1A)-adrenoceptors mediate sympathetically evoked pupillary dilation in rats. | 2002 Feb |
|
5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain. | 2002 Oct 4 |
|
Interaction between neuropeptide Y Y1 receptors and alpha1B-adrenoceptors in the neurovascular junction of canine splenic arteries. | 2003 Apr 18 |
|
Evidence for the role of alpha1D- and alpha1A-adrenoceptors in contraction of the rat mesenteric artery. | 2003 Feb |
|
Cytosolic Ca2+ and phosphoinositide hydrolysis linked to constitutively active alpha 1D-adrenoceptors in vascular smooth muscle. | 2003 Jun |
|
Chromatography studies on bio-affinity of nine ligands of alpha1-adrenoceptor to alpha1D subtypes overexpressed in cell membrane. | 2004 Aug |
|
Cloned human 5-HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation. | 2004 Oct |
|
Effects of alpha1D-adrenergic receptors on shedding of biologically active EGF in freshly isolated lacrimal gland epithelial cells. | 2006 Nov |
|
Alpha1A-adrenoceptors predominate in the control of blood pressure in mouse mesenteric vascular bed. | 2007 Jul |
|
Inhibitory effect of fentanyl on phenylephrine-induced contraction of the rat aorta. | 2009 Jun 30 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176444
Rats: BMY-7378 dose dependently (0.25-5 mg/kg s.c.) reduces the undetectable levels forepaw treading and head weaving induced by 8-OH-DPAT (0.75 mg/kg s.c.) in rats.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1535319
BMY-7378 at concentration of 1 nM to 30 nM elicits inhibitory effects in a concentration-dependent manner in the rat dorsal raphe nucleus.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
08EI0K81OL
Created by
admin on Fri Dec 15 18:41:40 GMT 2023 , Edited by admin on Fri Dec 15 18:41:40 GMT 2023
|
PRIMARY | |||
|
DTXSID70943430
Created by
admin on Fri Dec 15 18:41:40 GMT 2023 , Edited by admin on Fri Dec 15 18:41:40 GMT 2023
|
PRIMARY | |||
|
2419
Created by
admin on Fri Dec 15 18:41:40 GMT 2023 , Edited by admin on Fri Dec 15 18:41:40 GMT 2023
|
PRIMARY | |||
|
21102-94-3
Created by
admin on Fri Dec 15 18:41:40 GMT 2023 , Edited by admin on Fri Dec 15 18:41:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)